Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.46 |
| ▸ | CALML3 | P27482 | 7/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | SDHA | P31040 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6608322 | 1.00 | F10 (0.46) | F10CALML3KCNH2MAOBMAOA | |
| SCHEMBL6773589 | 0.89 | F10 (0.46) | F10CALML3MAOBMAOA | |
| SCHEMBL6685151 | 0.89 | CALML3 (0.57) | CALML3KCNH2MAOBMAOALMNA | |
| SCHEMBL6685146 | 0.89 | CALML3 (0.57) | CALML3KCNH2MAOBMAOALMNA | |
| SCHEMBL6607861 | 0.89 | F10 (0.46) | F10CALML3MAOBMAOA | |
| SCHEMBL6608964 | 0.85 | CALML3 (0.42) | F10CALML3KCNH2MAOBMAOA | |
| SCHEMBL6607285 | 0.84 | F10 (0.48) | F10CALML3MAOBMAOALMNA | |
| SCHEMBL6677965 | 0.83 | MAOB (0.62) | F10CALML3MAOBMAOALMNA | |
| SCHEMBL6606336 | 0.83 | MAOA (0.62) | F10CALML3MAOBMAOALMNA | |
| SCHEMBL6607264 | 0.82 | F10 (0.53) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448536-A1 | CYCLOPROPYL-CONTAINING OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | Merck & Co., Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| US-6686363-B2 | EFFECTIVE AGAINST MULTI-RESISTANT BACTERIA | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2004-02-03 | — | — | US | disclosed |
| US-20030225107-A1 | CYCLOPROPYL CONTAINING OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK SHARP & DOHME CORP. | 2003-12-04 | — | — | US | disclosed |
| WO-2003048136-A1 | CYCLOPROPYL HEXANE CONTAINING OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK & CO., INC. (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225107-A1 | CYCLOPROPYL CONTAINING OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | ALAD, OXA1L, ECI1 | F10 3591/4885CALML3 3713/4885KCNH2 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.